Home » LILLY'S LYMPHOMA DRUG MOVES TO PHASE III TRIAL
LILLY'S LYMPHOMA DRUG MOVES TO PHASE III TRIAL
Eli Lilly has launched a Phase III trial of enzastaurin in patients with non-Hodgkin's lymphoma.
In the trial, which is known as Preventing Relapse in Lymphoma Using Daily Enzastaurin, or PRELUDE, 459 patients with diffuse large B-cell lymphoma who have achieved remission following first-line therapy will be given either enzastaurin or placebo for up to three years.
The primary endpoint is disease-free survival, and investigators also will be looking for biomarkers that could help correlate patient response to clinical trial outcome.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May